Zhejiang Medicine Co Ltd (600216) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Medicine Co Ltd (600216) has a cash flow conversion efficiency ratio of 0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥690.77 Million ≈ $101.08 Million USD) by net assets (CN¥11.21 Billion ≈ $1.64 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 600216 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Zhejiang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Zhejiang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhejiang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Medicine Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MicroPort Scientific Corporation
F:MSK
|
-0.055x |
|
HuBei SanFeng Intelligent Conveying Equipment Co Ltd
SHE:300276
|
0.100x |
|
Shenzhen Zhenye Group Co Ltd
SHE:000006
|
-0.037x |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
0.076x |
|
Petrovietnam Power Corp
VN:POW
|
-0.080x |
|
Fujian Snowman Co Ltd
SHE:002639
|
-0.035x |
|
Siltronic AG
XETRA:WAF
|
0.027x |
|
Shenzhen Rayitek Hi-Tech Film Co. Ltd. A
SHG:688323
|
0.017x |
Annual Cash Flow Conversion Efficiency for Zhejiang Medicine Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Medicine Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Zhejiang Medicine Co Ltd (600216) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥11.09 Billion ≈ $1.62 Billion |
CN¥1.89 Billion ≈ $275.95 Million |
0.170x | +51.08% |
| 2024-12-31 | CN¥10.87 Billion ≈ $1.59 Billion |
CN¥1.22 Billion ≈ $179.01 Million |
0.113x | +77.21% |
| 2023-12-31 | CN¥9.99 Billion ≈ $1.46 Billion |
CN¥634.31 Million ≈ $92.82 Million |
0.064x | +18.47% |
| 2022-12-31 | CN¥9.71 Billion ≈ $1.42 Billion |
CN¥520.60 Million ≈ $76.18 Million |
0.054x | -56.69% |
| 2021-12-31 | CN¥9.18 Billion ≈ $1.34 Billion |
CN¥1.14 Billion ≈ $166.33 Million |
0.124x | -20.90% |
| 2020-12-31 | CN¥8.03 Billion ≈ $1.18 Billion |
CN¥1.26 Billion ≈ $183.90 Million |
0.157x | +188.76% |
| 2019-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥447.25 Million ≈ $65.45 Million |
0.054x | -24.45% |
| 2018-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
CN¥579.91 Million ≈ $84.86 Million |
0.072x | +10.84% |
| 2017-12-31 | CN¥7.78 Billion ≈ $1.14 Billion |
CN¥503.47 Million ≈ $73.67 Million |
0.065x | +34.62% |
| 2016-12-31 | CN¥6.99 Billion ≈ $1.02 Billion |
CN¥336.14 Million ≈ $49.19 Million |
0.048x | +198.51% |
| 2015-12-31 | CN¥6.62 Billion ≈ $968.00 Million |
CN¥106.54 Million ≈ $15.59 Million |
0.016x | -80.78% |
| 2014-12-31 | CN¥6.56 Billion ≈ $960.18 Million |
CN¥549.90 Million ≈ $80.47 Million |
0.084x | -17.10% |
| 2013-12-31 | CN¥6.48 Billion ≈ $948.29 Million |
CN¥655.09 Million ≈ $95.86 Million |
0.101x | -22.42% |
| 2012-12-31 | CN¥6.20 Billion ≈ $906.81 Million |
CN¥807.49 Million ≈ $118.16 Million |
0.130x | -37.18% |
| 2011-12-31 | CN¥4.40 Billion ≈ $643.92 Million |
CN¥912.75 Million ≈ $133.56 Million |
0.207x | -39.12% |
| 2010-12-31 | CN¥3.86 Billion ≈ $565.33 Million |
CN¥1.32 Billion ≈ $192.62 Million |
0.341x | -33.46% |
| 2009-12-31 | CN¥2.86 Billion ≈ $418.70 Million |
CN¥1.47 Billion ≈ $214.39 Million |
0.512x | -22.67% |
| 2008-12-31 | CN¥1.81 Billion ≈ $265.19 Million |
CN¥1.20 Billion ≈ $175.59 Million |
0.662x | +154.11% |
| 2007-12-31 | CN¥873.73 Million ≈ $127.85 Million |
CN¥227.67 Million ≈ $33.32 Million |
0.261x | +19.49% |
| 2006-12-31 | CN¥777.31 Million ≈ $113.74 Million |
CN¥169.51 Million ≈ $24.80 Million |
0.218x | +535.06% |
| 2005-12-31 | CN¥732.23 Million ≈ $107.15 Million |
CN¥25.14 Million ≈ $3.68 Million |
0.034x | -79.39% |
| 2004-12-31 | CN¥645.68 Million ≈ $94.48 Million |
CN¥107.60 Million ≈ $15.75 Million |
0.167x | +58.20% |
| 2003-12-31 | CN¥628.48 Million ≈ $91.97 Million |
CN¥66.20 Million ≈ $9.69 Million |
0.105x | +186.82% |
| 2002-12-31 | CN¥629.71 Million ≈ $92.15 Million |
CN¥23.13 Million ≈ $3.38 Million |
0.037x | -77.25% |
| 2001-12-31 | CN¥608.50 Million ≈ $89.04 Million |
CN¥98.25 Million ≈ $14.38 Million |
0.161x | +868.83% |
| 2000-12-31 | CN¥635.03 Million ≈ $92.92 Million |
CN¥10.58 Million ≈ $1.55 Million |
0.017x | +120.07% |
| 1999-12-31 | CN¥625.07 Million ≈ $91.47 Million |
CN¥-51.90 Million ≈ $-7.60 Million |
-0.083x | -150.15% |
| 1998-12-31 | CN¥348.61 Million ≈ $51.01 Million |
CN¥57.72 Million ≈ $8.45 Million |
0.166x | -- |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition produ… Read more